Patients with dual-positive anti-Ro52/Ro60 antibodies showed a markedly higher risk of several systemic complications, particularly sicca symptoms, interstitial lung disease (ILD), and hematologic involvement, compared to the double-negative group. This evidence concerns the gene TRIM21 and interstitial lung disease.